| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Acurx Pharmaceuticals, Inc.$1.5
+0.08 (+5.72%)
D 27Pipeline Score Richly Valued Pharma · Clinical
Market Cap
7.74 M
EPS
-4.40
P/E Ratio
-0.41 $
Value Trade
206.42 K
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
341.47 K
Operating CF
-1.41 M
Total Assets
9.54 M
Total Liabilities
2.53 M
Equity
7.01 M
D/E Ratio
12,345
0.51 %
Week
-15.09 %
1 Month
5.35 %
3 Month
-50 %
6 Month
-98.34 %
5 Year
-98.34 %
All Time
Cash Data
Cash Position
9.25 M
Monthly Burn
469.00 K
Runway
17.9 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
89.73 K
52 Week Range
1.33 - 21
% held by Insiders
8.12 %
% held by Institutions
4.23 %
Enterprise Value
-1.52 M
Total Shares
4.30 M
Short %
3.57 %
Float Shares
3.80 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Acurx Pharmaceuticals, Inc.
283Total events
5Upcoming
35Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 5
TBD
T2Timing Guidance
Phase 3 international pivotal trials in acute CDI ready to advance subject to financing
Event history 278
Jul 7, 2026
◆AbstractIbezapolstatPresentation
Abstract submission to Anaerobe Society of the Americas conference
C. difficile infectionsource ↗
Jun 11, 2026
▲Oral PresentationIbezapolstatPresentation
Presentation of cryo-EM structure of ibezapolstat bound to DNA pol IIIC at LED3 conference
Gram-positive bacterial infectionssource ↗
May 4, 2026
▲Partnership / LicenseCorporate
Research grant from Dutch government to Leiden University Medical Center and Acurx for DNA pol IIIC inhibitors
Gram-positive infectionssource ↗
Apr 17, 2026
▲Poster PresentationPresentation
Poster presentation of preclinical microbiome evaluation of DNA pol IIIC inhibitors at ESCMID Global 2026
Gram-positive infectionssource ↗
Apr 16, 2026
▼Equity OfferingCorporate
Closing of registered direct offering raising $2.5 million upfront with potential additional $4.6 million from warrant exercise
Apr 2026
▼Equity OfferingCorporate
Closed registered direct offering of 825,085 shares at $3.03 per share and concurrent private placement of warrants
Apr 2026
●Poster PresentationIbezapolstatPresentation
Poster presented at ESCMID Global 2026 showing gut microbiome preservation and systemic antibacterial activity of oral DNA pol IIIC inhibitors
Gram-positive bacterial infectionssource ↗
Mar 30, 2026
▲Patent GrantedACX-375CIP / Competition
Korean Patent Office grants patent for DNA Polymerase IIIC inhibitors covering ACX-375C program
Mar 13, 2026
Mar 13, 2026
▲Trial InitiationIbezapolstatTrial
Launch of open-label pilot trial in multiply-recurrent CDI
multiply-recurrent C. difficile Infection (rCDI)source ↗
Mar 9, 2026
◆Trial InitiationIbezapolstatTrial
Initiation of open-label pilot trial in patients with multiply-recurrent CDI
recurrent C. difficile infection (rCDI)source ↗
Drug Pipeline Intelligence
D27
Pipeline Score $1M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 30%
Micro Cap (rank 639 of 911)
Percentile RankAcurx Pharmaceuticals, Inc. faces pipeline headwinds (27/100), with $72M risk-adjusted pipeline value, led by Ibezapolstat in Clostridium Difficile Infection (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ibezapolstat Small molecule | Clostridium Difficile Infection | Phase 2 | NCT04247542 | 14% | $72M | COMPLETED | 53 | - | - | Nov 15, 2023 | - | Jan 17, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ibezapolstat Fast Track | C. difficile infection | Phase 3 | 2026-06-16 | High-resolution cryo-electron microscopy resolved the structure of ibezapolstat in relationship to the binding pocket of a Gram-positive DNA pol IIIC to the level of 3.2Å; The active site of the polymerase is conserved in >220 Gram-positive species Read More | Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference Read More | |
ibezapolstat Fast Track | C. difficile infection | Phase 3 | 2026-06-16 | High-resolution cryo-electron microscopy resolved the structure of ibezapolstat in relationship to the binding pocket of a Gram-positive DNA pol IIIC to the level of 3.2Å; The active site of the polymerase is conserved in >220 Gram-positive species Read More | Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference Read More | |
ibezapolstat Fast Track | C. difficile infection | Phase 3 | 2026-06-16 | High-resolution cryo-electron microscopy resolved the structure of ibezapolstat in relationship to the binding pocket of a Gram-positive DNA pol IIIC to the level of 3.2Å; The active site of the polymerase is conserved in >220 Gram-positive species Read More | Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ACXP
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ACXP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ACXP▼ -6.2%on this news
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
Acurx Pharmaceuticals will discuss its second quarter 2026 financial results on August 14, 2026. The call will be hosted by CEO David P. Luci and CFO Robert G. Shawah. The company is advancing its lead antibiotic candidate, ibezapolstat, into international Phase 3 trials for treating C. difficile infections, following FDA designations that support its development.
Read more →ACXPAcurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
Acurx Pharmaceuticals announced positive results from its collaboration with Leiden University Medical Center regarding its DNA pol IIIC inhibitors. The findings, presented at the LED3 Scientific Conference, highlight the potential of ibezapolstat as a targeted treatment for Gram-positive bacterial infections. The company is preparing to advance ibezapolstat into international Phase 3 clinical trials for C. difficile infection.
Read more →ACXP▼ -6%on this news
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
Acurx Pharmaceuticals reported its Q1 2026 results, highlighting a new patent for DNA pol IIIC inhibitors and the initiation of a clinical trial for recurrent CDI. The company achieved a 96% clinical cure rate in previous trials and is preparing for a Phase 3 trial pending favorable outcomes. Despite a net loss of $1.7 million, Acurx has secured funding for its clinical programs.
Read more →ACXPAcurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
Acurx Pharmaceuticals announced the presentation of a scientific poster at the ESCMID Global 2026, showcasing the microbiome evaluation of its DNA pol IIIC inhibitors. The findings suggest these compounds effectively target resistant Gram-positive infections while preserving gut microbiome integrity. This could lead to significant advancements in antibiotic therapy, minimizing complications associated with traditional antibiotics.
Read more →ACXPAcurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
Acurx Pharmaceuticals will present at the A.G.P. Healthcare Company Showcase on May 24, 2025. CEO David P. Luci will participate in a virtual fireside chat. The company is focused on developing a new class of antibiotics, with its lead candidate ibezapolstat ready for Phase 3 trials targeting recurrent C. difficile infections.
Read more →ACXPAcurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
Acurx Pharmaceuticals announced a conference call on May 12, 2026, to discuss its Q1 financial results and provide a business update. The company is advancing its lead antibiotic candidate, ibezapolstat, into international Phase 3 trials for treating C. difficile infections. Acurx has secured regulatory agreements for its trial designs from both the EMA and FDA.
Read more →ACXPAcurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals, Inc. has announced the closing of a registered direct offering, raising $2.5 million upfront, with potential additional proceeds of $4.6 million from short-term warrants. The funds will support working capital and corporate purposes. Acurx's lead antibiotic candidate, ibezapolstat, is set to advance to Phase 3 trials for treating C. difficile infections.
Read more →ACXP▼ -19.7%on this newsshared move
Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals announced a registered direct offering of up to $7.1 million, which includes $2.5 million upfront and potential additional proceeds from short-term warrants. The funds will be used for working capital and advancing their antibiotic candidate, ibezapolstat, into clinical trials. The offering is subject to customary closing conditions and is expected to close on April 16, 2026.
Read more →ACXP▼ -6.9%on this news
Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
Acurx Pharmaceuticals has received a new patent from the Korean Intellectual Property Office for its DNA Polymerase IIIC inhibitors. This patent enhances Acurx's intellectual property portfolio, which includes multiple patents in various countries. The company is preparing to advance its lead compound, ibezapolstat, to Phase 3 trials for treating acute C. difficile infection.
Read more →ACXP▼ -22.6%on this news
Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update
Acurx Pharmaceuticals reported its financial results for the fourth quarter and full year ended December 31, 2025, highlighting a significant improvement in cash position and reduced expenses. The company is preparing for international Phase 3 clinical trials for its lead antibiotic candidate, ibezapolstat, which has received positive feedback from the EMA. However, Acurx continues to face net losses and must secure financing to advance its clinical programs.
Read more →ACXP▲ +44.8%on this news· ran to +271% by day 3
Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection
Acurx Pharmaceuticals has announced a new clinical trial program for ibezapolstat, targeting recurrent Clostridioides difficile infection (rCDI). The program includes an open-label pilot trial followed by a Phase 3 registration trial, pending funding. The company aims to demonstrate ibezapolstat's effectiveness in both treating and preventing rCDI, potentially shifting treatment paradigms. Positive Phase 2 results support their confidence in advancing the drug.
Read more →ACXPAcurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update
Acurx Pharmaceuticals will discuss its 2025 financial results and provide a business update on March 13, 2026. The company is advancing its lead antibiotic candidate, ibezapolstat, into international Phase 3 trials for treating C. difficile infections. Regulatory guidance from both the EMA and FDA has been positive, supporting the trial's design and objectives.
Read more →ACXPUSPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
Acurx Pharmaceuticals has received a new patent for DNA Polymerase IIIC inhibitors, enhancing its intellectual property portfolio. This patent covers various methods and compositions related to their antibiotic development. The company's lead candidate, ibezapolstat, is ready for Phase 3 trials targeting C. difficile infections, with promising preclinical data for additional antibiotic candidates.
Read more →ACXPHealth~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals
Acurx Pharmaceuticals has received a $375,000 grant from Health~Holland for a research project in collaboration with Leiden University Medical Center. The project focuses on developing a new class of antibiotics targeting DNA polymerase IIIC inhibitors, which could provide new treatment options for multidrug-resistant bacterial infections. The research aims to enhance understanding of the structure and function of these inhibitors, paving the way for future drug development.
Read more →ACXP▼ -10.8%on this news· ran to -24% by day 3
Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update
Acurx Pharmaceuticals reported its third quarter results for 2025, showing a cash position increase to $5.9 million and a significant reduction in R&D expenses. The company is preparing for international Phase 3 clinical trials for its lead antibiotic candidate, ibezapolstat, following positive regulatory feedback from the EMA. However, Acurx continues to face net losses, reporting $2.0 million for the quarter.
Read more →ACXP▲ +11%on this newsshared move
Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens
Acurx Pharmaceuticals announced a publication in Nature Communications detailing the structural biology research of its DNA pol IIIC inhibitor, ibezapolstat. This research provides insights into its mechanism of action and supports the development of new antibiotics targeting Gram-positive pathogens. The company is advancing ibezapolstat towards Phase 3 clinical trials following positive feedback from regulatory authorities.
Read more →ACXPAcurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference
Acurx Pharmaceuticals presented new data on its DNA pol IIIC inhibitor antibiotics at IDWeek 2025, showcasing their potential to selectively spare the gut microbiome while treating serious bacterial infections. The findings suggest a class effect that could enhance treatment efficacy and reduce recurrence rates of infections like C. difficile. The company is preparing for international Phase 3 trials for its lead candidate, ibezapolstat.
Read more →ACXPAcurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update
Acurx Pharmaceuticals will hold a conference call on November 12, 2025, to discuss its Q3 2025 financial results and provide a business update. The company is advancing its lead antibiotic candidate, ibezapolstat, into international Phase 3 trials for treating C. difficile infections, following positive feedback from regulatory bodies. The drug has received QIDP and Fast Track designations from the FDA.
Read more →ACXP▼ -8.1%on this news
Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
Acurx Pharmaceuticals has been granted a new patent by the Australian Patent Office for its DNA Polymerase IIIC inhibitors, adding to its existing patents in multiple countries. This patent protects Acurx's innovative antibiotic candidates aimed at treating difficult bacterial infections, including those caused by multidrug-resistant pathogens. The company's lead candidate is ready for Phase 3 trials targeting C. difficile infections.
Read more →ACXPAcurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection
Acurx Pharmaceuticals received a positive opinion from the EMA regarding its Pediatric Investigation Plan for ibezapolstat, aimed at treating children with C. difficile infection. This decision highlights the urgent need for effective antibiotics in pediatric care, particularly as CDI cases in children increase. The company plans to demonstrate ibezapolstat's safety and efficacy in upcoming clinical trials.
Read more →ACXPAcurx Pharmaceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Closing Bid Price and Stockholder Equity Rules
Acurx Pharmaceuticals, Inc. has announced that it has regained full compliance with Nasdaq's minimum closing bid price and stockholder equity rules. This compliance ensures that Acurx's common stock will continue to be listed on the Nasdaq Stock Market. The company is focused on developing innovative antibiotics and is preparing for international clinical trials for its lead candidate, ibezapolstat.
Read more →ACXPAcurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update
Acurx Pharmaceuticals, Inc. has reported its second quarter results for 2025, highlighting significant financial and operational advancements. Notably, the company received a new patent for its DNA polymerase IIIC inhibitors and closed an equity line of credit for up to $12 million. Ibezapolstat, the company's lead antibiotic candidate, is set to enter international Phase 3 trials following favorable regulatory guidance. Despite these advancements, Acurx continues to face financial losses.
Read more →ACXPAcurx Pharmaceuticals, Inc. Announces Reverse Stock Split
Acurx Pharmaceuticals, Inc. announced a 1-for-20 reverse stock split approved by stockholders to increase its stock price and comply with Nasdaq's minimum bid requirement. The split will take effect on August 4, 2025, reducing the number of outstanding shares significantly. The company continues to focus on developing antibiotics for difficult-to-treat infections.
Read more →ACXPAcurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update
Acurx Pharmaceuticals will discuss its Q2 2025 financial results on August 12, 2025. The company is preparing for international Phase 3 trials of its lead antibiotic candidate, ibezapolstat, which targets C. difficile infections. Positive regulatory guidance from the EMA supports this advancement, and the FDA has granted ibezapolstat QIDP and Fast Track designations.
Read more →ACXP▼ -12.3%on this news· ran to -33% by day 1
C O R R E C T I O N -- Acurx Pharmaceuticals, Inc./ PR Newswire
Acurx Pharmaceuticals, Inc. has announced the exercise of warrants resulting in gross proceeds of approximately $2.67 million, after an amendment to the exercise price. The company is expecting the transaction to close by June 20, 2025. Acurx intends to utilize these funds for working capital and general corporate purposes. The exercise of warrants includes the issuance of new warrants, which could potentially dilute stock value, but also reflects investor confidence in Acurx's antibiotic candidate, Ibezapolstat, which is moving towards international clinical trials.
Read more →ACXP▼ -12.3%on this news· ran to -33% by day 1
Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds
Acurx Pharmaceuticals, Inc. has entered into a warrant inducement agreement resulting in $2.67 million gross proceeds from existing warrants. Investors agreed to exercise the warrants at a reduced price, while receiving new G-1 and G-2 warrants as part of the deal. The transaction is expected to close by June 20, 2025, and the funds will be utilized for working capital and corporate purposes. Acurx is advancing its lead antibiotic candidate, ibezapolstat, to international Phase 3 trials for treating C. difficile infection.
Read more →ACXP▲ +167.2%on this newsshared move
Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI
Acurx Pharmaceuticals announced the publication of Phase 2b clinical trial data for ibezapolstat in the Lancet Microbe, highlighting significant efficacy in treating C. difficile infection. The results showed a 94% Clinical Cure rate, with patients remaining free of infection recurrence one month post-treatment. The study indicates that ibezapolstat preserves beneficial gut microbiota, setting a promising stage for upcoming international Phase 3 trials, backed by favorable regulatory feedback. This positions Acurx as a strong contender in addressing the pressing need for new antibiotic treatments in the current landscape.
Read more →ACXPAcurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference
Acurx Pharmaceuticals has announced the presentation of promising results from its collaboration with Leiden University Medical Center on its DNA pol IIIC inhibitors. The lead drug, ibezapolstat, is set to enter pivotal Phase 3 clinical trials for the treatment of C. difficile infection. The drug has already received important designations from the FDA and EMA, indicating its potential in addressing hard-to-treat bacterial infections. Research findings presented at a recent scientific conference suggest valuable insights into the drug's mechanism of action, which could aid in developing new compounds to combat antimicrobial resistance.
Read more →ACXPAcurx Pharmaceuticals, Inc. Reports First Quarter Results and Provides Business Update
Acurx Pharmaceuticals, Inc. reported financial and operational results for Q1 2025, highlighting a net loss of $2.1 million. The company received positive regulatory guidance for its lead candidate, ibezapolstat, from the European Medicines Agency, which aligns with feedback from the FDA as they prepare for Phase 3 trials. Recent studies show promising results for ibezapolstat in treating C. difficile infections, and Acurx secured additional funding through an equity line of credit. Overall, the developments position Acurx favorably as they embark on critical clinical trials.
Read more →ACXP7:01 am ET on Tuesday
Acurx Pharmaceuticals, Inc. announced its financial results for the first quarter of 2025, reporting a net loss of $2.1 million, significantly reduced from $4.4 million in Q1 2024. The company ended the quarter with $4.6 million in cash following a successful fundraising round. Acurx is progressing with its lead antibiotic candidate, Ibezapolstat, which is now entering Phase 3 clinical trials for Clostridioides difficile infection, supported by FDA designations like QIDP and Fast Track.
Read more →ACXPAcurx Pharmaceuticals to Discuss First Quarter 2025 Financial Results on May 13, 2025 Conference Call and Provide Business Update
Acurx Pharmaceuticals will discuss its financial results for the first quarter of 2025 on May 13, 2025, as well as provide a business update. The company is advancing its lead antibiotic candidate, ibezapolstat, into international Phase 3 clinical trials for treating C. difficile infections. Recent interactions with regulatory agencies like the EMA and FDA have been positive, suggesting a strong potential for moving forward with their clinical programs. Ibezapolstat is positioned as a unique treatment, aimed at addressing the urgent medical need for new antibiotics.
Read more →ACXPIndian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
Acurx Pharmaceuticals, Inc. announced the granting of a new patent by the Indian Patent Office for its DNA Polymerase IIIC inhibitors. This patent adds to a growing portfolio of patents aimed at protecting their innovative antibiotic candidates, particularly for difficult-to-treat bacterial infections. Acurx's lead candidate is poised for Phase 3 clinical trials targeting C. difficile infections. The company is focused on the development of a new class of antibiotics with a selective spectrum against Gram-positive bacteria, which includes antibiotic-resistant strains.
Read more →ACXP▼ -14.2%on this news
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
Acurx Pharmaceuticals, Inc. has reported its fourth quarter and full year 2024 results, highlighting positive developments for its lead antibiotic candidate, ibezapolstat. The drug has demonstrated high clinical cure rates in clinical trials against Clostridioides difficile infection. The company received favorable regulatory guidance from the European Medicines Agency which positions it well for future Phase 3 trials. However, Acurx also reported a net loss for the year and a decline in cash reserves.
Read more →ACXPAcurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering
Acurx Pharmaceuticals, Inc. has announced the closing of its registered direct offering, raising approximately $1.1 million through the sale of 2,745,000 shares of common stock at $0.40 each. Concurrently, the company issued unregistered short-term warrants to purchase 8,235,000 shares of common stock. The proceeds from this offering will be utilized for working capital and general corporate purposes. Acurx continues to focus on developing a new class of antibiotics targeting difficult-to-treat bacterial infections, including a lead candidate ready for Phase 3 clinical trials.
Read more →ACXP▼ -29.9%on this newsshared move
Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering Staten Island, NY
Acurx Pharmaceuticals, Inc. announced a $1.1 million registered direct offering, issuing 2,745,000 shares of common stock at $0.40 per share. The closing is expected on or about March 10, 2025, subject to customary conditions. Proceeds from the offering will be used for working capital and corporate purposes as Acurx continues its efforts to develop new antibiotics for difficult-to-treat bacterial infections. This funding comes at a crucial time as the company prepares for clinical trials of its lead antibiotic candidate, ibezapolstat.
Read more →ACXP▼ -5.5%on this news
Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat
Acurx Pharmaceuticals announced the publication of a study revealing the differentiating effects of ibezapolstat on the gut microbiome when compared to other antibiotics used for C. difficile infections. The study, published in a respected journal, indicates that ibezapolstat has a more selective impact on microbiome diversity than broader-spectrum antibiotics such as vancomycin and metronidazole. These findings support the company's advancement of ibezapolstat into international Phase 3 clinical trials, with previous positive regulatory feedback from both the FDA and EMA.
Read more →ACXPAcurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update
Acurx Pharmaceuticals will hold a conference call on March 18, 2025, to discuss its fourth quarter and full-year financial results for 2024. The company is preparing to advance its lead antibiotic candidate, ibezapolstat, into international Phase 3 clinical trials for treating C. difficile infection (CDI). Acurx has received favorable feedback from both the EMA and FDA regarding its clinical trial plans and could submit a Marketing Authorization Application if trials succeed. This advancement responds to the urgent need for new antibiotics as highlighted by the CDC.
Read more →ACXP▲ +8.3%on this news
Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI
Acurx Pharmaceuticals announced positive results from an in-silico study which predicts the microbiome-restorative potential of its antibiotic, ibezapolstat, for treating Clostridioides difficile Infection (CDI). The study provides insights into ibezapolstat's selectivity and its interaction with beneficial gut microbiota. Following favorable regulatory feedback from the EMA, the company is set to advance into international Phase 3 clinical trials. The study, published in a prominent journal, was conducted by researchers from the University of Houston and funded by the NIH.
Read more →ACXPJPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors
Acurx Pharmaceuticals has announced the granting of a new patent by the Japanese Patent Office for DNA Polymerase IIIC Inhibitors. This patent supports the company's ongoing development of innovative antibiotics aimed at treating difficult-to-treat bacterial infections. The newly approved patent is part of Acurx's broader strategy to protect its technologies and enhance its global patent portfolio, which also includes patents from the U.S. and Israel. The company is currently preparing for international Phase 3 clinical trials following encouraging results in earlier studies of its lead candidate, ibezapolstat, for the treatment of C. difficile Infection.
Read more →ACXP▼ -26%on this news
Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Acurx Pharmaceuticals has announced the closure of a registered direct offering, raising approximately $2.5 million through the sale of 2,463,058 shares at $1.015 each. The funds will be utilized for working capital and other corporate purposes. Notably, Acurx is advancing its lead product candidate, ibezapolstat, towards Phase 3 clinical trials, aiming to target difficult-to-treat bacterial infections, with plans for international trials underway.
Read more →ACXP▲ +22.5%on this newsshared move
Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Staten Island, NY
Acurx Pharmaceuticals, Inc. has announced a $2.5 million registered direct offering of its common stock priced at $1.015 per share. The offering includes unregistered warrants that will enable the purchase of additional shares at $0.90 each. The net proceeds are earmarked for working capital and general corporate uses. This move follows the company's strategy to develop innovative antibiotics for challenging bacterial infections, including their lead candidate now gearing up for clinical trials.
Read more →ACXP▲ +22.5%on this newsshared move
Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)
Acurx Pharmaceuticals has received positive regulatory guidance from the European Medicines Agency (EMA) for its lead antibiotic candidate, ibezapolstat, in the treatment of C. difficile infection (CDI). This support assists Acurx in advancing its Phase 3 clinical trials, with preparations to seek further regulatory approval in multiple countries. The company has also been granted FDA Fast-Track Designation, indicating strong potential for their drug in addressing difficult-to-treat bacterial infections.
Read more →ACXP▲ +18%on this news
Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications
Acurx Pharmaceuticals has made significant strides towards Phase 3 clinical trials for its antibiotic candidate, ibezapolstat, targeting C. difficile Infection. Following positive feedback from the FDA on its Chemistry Manufacturing and Controls plan, the company is also in discussions with the EMA for further guidance. The Phase 3 international trials aim to utilize advanced technology to enhance patient enrollment, and Acurx is preparing requests for regulatory guidance across several countries including Japan, Canada, and the UK. The successful Phase 2 trials demonstrated promising clinical outcomes, further supporting Acurx's optimistic future in the biopharmaceutical landscape.
Read more →ACXP▼ -6.5%on this news· ran to -18% by day 3
Acurx-Vorstand genehmigt die Verwendung von Bitcoin als Währungsreserve
Acurx Pharmaceuticals has approved the purchase of up to $1 million in Bitcoin as a currency reserve. CEO David P. Luci believes that Bitcoin's increasing demand and acceptance make it a valuable asset for unused cash, despite its inherent volatility risks. While this financial strategy aims to strengthen the company's treasury, it does not affect Acurx's ongoing drug development plans. The decision aligns with growing support for Bitcoin among institutional investors and regulatory bodies.
Read more →ACXP▼ -16.8%on this newsshared move
Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset
Acurx Pharmaceuticals has approved the purchase of up to $1 million in Bitcoin as a treasury reserve asset. The company's President & CEO, David P. Luci, believes that Bitcoin's growing acceptance and its qualities as a limited supply asset position it as a beneficial component of their treasury strategy. Despite this positive financial move, Acurx emphasizes that this decision does not alter their primary focus on drug development, particularly their new class of antibiotics targeting difficult bacterial infections. The company acknowledges potential volatility risks associated with Bitcoin investments, as well as factors that could affect its drug development pipeline.
Read more →ACXP▼ -16.8%on this newsshared move
La junta directiva de Acurx aprueba Bitcoin como activo de reserva de tesorería
Acurx Pharmaceuticals has announced the approval from its Board of Directors to purchase up to $1 million in Bitcoin as a treasury reserve asset. This move is seen as part of a strategy to leverage Bitcoin's growing acceptance and perceived value as a hedge against inflation. The company emphasizes that this financial strategy will not affect its overall drug development plans. However, it also acknowledges the inherent risks associated with investing in Bitcoin, including its volatility and the uncertainties surrounding its drug candidate ibezapolstat.
Read more →ACXP▼ -16.8%on this newsshared move
Le conseil d
Acurx Pharmaceuticals, Inc. has announced the approval of its board to purchase up to one million dollars in Bitcoin as a treasury reserve asset. The CEO, David P. Luci, stated that the increasing demand for Bitcoin and its acceptance as a primary asset class positions it as a solid cash reserve. Importantly, this strategy will not affect the company's ongoing drug development plans. However, there are inherent risks associated with Bitcoin's volatility and the execution of this new cash strategy.
Read more →ACXPAcurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update
Acurx Pharmaceuticals sponsored the inaugural Peggy Lillis Foundation Scientific Symposium and presented updates on its lead antibiotic candidate, ibezapolstat. The company is preparing to advance ibezapolstat into international Phase 3 clinical trials for treating C. difficile Infection (CDI), following promising Phase 2 results that indicate a high Clinical Cure rate. The updates shared at the symposium included insights into the drug's microbiome impact and the anticipated regulatory steps for approval in international markets. Acurx continues to prepare for Phase 3 trials while emphasizing the unmet need in CDI treatment.
Read more →ACXP7:01 am ET on Wednesday
Acurx Pharmaceuticals, Inc. released its third quarter results for 2024, indicating a net loss of $2.8 million, an improvement over the previous year's loss. The company ended the quarter with $5.8 million in cash and reported increased research and development expenses compared to the previous year. Acurx is advancing its lead antibiotic candidate, ibezapolstat, towards Phase 3 clinical trials for treating C. difficile infections. Despite positive developments, the company continues to face financial challenges.
Read more →ACXPAcurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update
Acurx Pharmaceuticals, Inc. reported its third quarter 2024 financial results and provided a business update highlighting advancements in their antibiotic ibezapolstat for C. difficile infections. Key developments include positive Phase 2 trial results and the granting of a new patent for ibezapolstat, which will expire in June 2042. The company plans to start international Phase 3 trials soon, following FDA discussions on manufacturing processes. However, Acurx also reported a net loss and reduced cash reserves, indicating financial challenges.
Read more →ACXPAcurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference
Acurx Pharmaceuticals presented promising data from its Phase 2b trial of ibezapolstat for C. difficile infection during the IDWeek 2024 Conference. The data indicated favorable gut bile acid profiles and a restoration of beneficial gut bacteria, which could enhance the drug's anti-recurrence effects. Acurx is preparing for international Phase 3 trials and has already established agreements with the FDA for further development. The company expressed confidence that the positive Phase 2 results will translate into successful Phase 3 outcomes.
Read more →ACXPAcurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement
Acurx Pharmaceuticals, Inc. has announced its participation at the Spartan Capital inaugural investor conference on November 4, 2024, in New York City. The event will provide a platform for the company to present its growth strategy and market position to key investors. David P. Luci, the company's President & CEO, is enthusiastic about the opportunity to engage with industry leaders and share the company's accomplishments and future plans. The conference will gather over 30 companies and include various interactive sessions.
Read more →ACXPAcurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024
Acurx Pharmaceuticals has announced a conference call scheduled for November 13, 2024, to discuss its third quarter financial results. The call will feature insights from CEO David P. Luci and CFO Robert G. Shawah. During this update, the company is expected to outline progress on ibezapolstat, its lead antibiotic candidate, which is advancing to Phase 3 clinical trials for the treatment of Clostridioides difficile infection (CDI). The product has received favorable designations from the FDA, underscoring its potential in the antibiotics market.
Read more →ACXP▲ +5.3%on this news
Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues
Acurx Pharmaceuticals announced positive Phase 2b results for ibezapolstat, demonstrating beneficial effects on the gut microbiome and confirming its favorable pharmacokinetics. The drug has shown in vitro activity against Anthrax and plans to initiate international Phase 3 clinical trials for treating C. difficile infection. Additionally, regulatory guidance requests are being prepared for trials in the European Union, UK, Japan, and Canada. Acurx has received FDA QIDP and Fast-Track Designation for ibezapolstat, enhancing its development profile.
Read more →ACXPAcurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium
Acurx Pharmaceuticals announced promising results from its research on ibezapolstat, developed in collaboration with Leiden University Medical Center. The findings highlight ibezapolstat's unique properties in targeting Clostridium difficile infections while avoiding cross-resistance with existing antibiotics. Plans are underway for international Phase 3 clinical trials in several regions, including the EU and Japan, following successful FDA meetings. The research underpins the potential for new antibiotic development amidst rising antimicrobial resistance.
Read more →ACXPACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference
Acurx Pharmaceuticals announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, taking place from September 9-11, 2024, in New York City. David P. Luci, President & CEO, will present an overview of the company's business, highlighting its focus on small molecule antibiotics designed to treat difficult bacterial infections. The event is expected to host over 550 company presentations, indicating a significant opportunity for Acurx to attract institutional investors. This marks an important step for the company as it seeks to advance its portfolio of antibiotic candidates targeting Gram-positive bacteria.
Read more →ACXPAcurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update
Acurx Pharmaceuticals reported its financial and operational results for the second quarter of 2024, highlighting their successful End-of-Phase 2 Clinical Meeting with the FDA, which confirmed the readiness for Phase 3 trials of ibezapolstat for treating C. difficile infections. The company received a new patent covering IBZ, improving its competitive stance in the market. However, Acurx faces financial challenges with a reported net loss of $4.1 million for the quarter and a decrease in cash reserves compared to the previous quarter. Regulatory preparations continue as the company aims to extend its reach internationally, with additional presentations planned at scientific conferences throughout the year.
Read more →ACXP7:01 am ET on Friday
Acurx Pharmaceuticals, Inc. announced its financial results and business updates for the second quarter of 2024. The company reported a net loss of $4.1 million and a cash balance of $6.4 million, showing a decline compared to the previous quarter. Upcoming presentations at significant conferences, including the World Antimicrobial Resistance conference and the ICDS meeting, highlight the company’s commitment to addressing challenging bacterial infections. The development of ibezapolstat, a novel antibiotic for C. difficile, continues, with the drug holding a QIDP designation from the FDA, providing it with important development incentives.
Read more →ACXP▲ +6.1%on this news
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome
Acurx Pharmaceuticals has received a new patent from the USPTO for ibezapolstat, aimed at treating C. difficile Infection (CDI) and improving gut microbiome health. The company is preparing to initiate Phase 3 clinical trials after successful FDA interactions, indicating strong progress in its development pipeline. The effectiveness of ibezapolstat in reducing CDI recurrence and restoring microbiome function is seen as a significant advancement over existing antibiotics. Acurx reports a high Clinical Cure rate from Phase 2 trials and anticipates demonstrating the non-inferiority of ibezapolstat to vancomycin in upcoming trials.
Read more →ACXPAcurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update
Acurx Pharmaceuticals, Inc. has announced a conference call scheduled for August 9, 2024, to discuss its second quarter financial results and provide a business update. The call will be hosted by CEO David P. Luci and CFO Robert G. Shawah. The company is focusing on its lead antibiotic candidate, Ibezapolstat, which is set for international Phase 3 clinical trials aimed at treating C. difficile infections. Ibezapolstat has received important designations from the FDA, including QIDP and Fast Track status, highlighting its potential in addressing urgent public health needs.
Read more →ACXPAcurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference
Acurx Pharmaceuticals presented results from its Phase 2 clinical trial of ibezapolstat for treating C. difficile Infection (CDI) at the Anaerobe Society Congress. The results demonstrated significant microbiome benefits and a high clinical cure rate of 96%. The company is preparing for a Phase 3 clinical program and has received FDA agreement on the trial's design and requirements. Experts anticipate that ibezapolstat could set a new standard in CDI treatment and antibiotic development.
Read more →ACXP▲ +7.7%on this news
Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection
Acurx Pharmaceuticals announced a successful End-of-Phase 2 meeting with the FDA for its antibiotic ibezapolstat, allowing the company to move forward with Phase 3 trials targeting C. difficile Infection. Key agreements have been made regarding trial design and endpoints. The successful Phase 2 results demonstrated a 96% Clinical Cure rate. Additionally, the company has received SME designation from the EMA, which offers benefits for EU marketing authorization efforts.
Read more →ACXP▲ +7.7%on this news
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
Acurx Pharmaceuticals reported its first-quarter financial and operational results for 2024, highlighting positive outcomes in the Phase 2b clinical trial of ibezapolstat against Clostridioides difficile infection. The drug demonstrated higher eradication rates of C. difficile compared to vancomycin. The company has secured FDA approval for its upcoming Phase 3 program and received SME designation from the EMA, which will assist in its marketing authorization efforts in Europe. However, Acurx also reported an increase in net loss and ongoing risks associated with clinical trials.
Read more →ACXPAcurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference
Acurx Pharmaceuticals presented results from their ibezapolstat Phase 2 clinical trial at the ESCMID Global 2024 conference. The findings demonstrated that ibezapolstat is comparable to vancomycin in treating Clostridioides difficile Infection (CDI), with no recurrences in patients who were cured. The drug's potential against antimicrobial-resistant strains was emphasized, and the findings will support further Phase 3 development. The company is also preparing to publish these results in a scientific journal.
Read more →ACXPAcurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference
Acurx Pharmaceuticals announced that results from their Phase 2 clinical trial of ibezapolstat for treating C. difficile infection would be presented at the ESCMID 2024 conference in Barcelona. The trial outcomes demonstrated a 96% clinical cure rate, indicating strong efficacy compared to vancomycin. The treatment was well-tolerated, with no serious adverse events reported. However, enrollment challenges due to COVID-19 impacted the trial's progression, yet the company remains optimistic about advancing to Phase 3 trials.
Read more →ACXPAcurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update
Acurx Pharmaceuticals, Inc. announced that it will discuss its first quarter 2024 financial results on May 15, 2024, during a conference call. The company is focused on its lead candidate, Ibezapolstat, which is set to advance to Phase 3 clinical trials for treating C. difficile Infection. This antibiotic has been recognized with both QIDP and Fast Track designations by the FDA, signaling its potential in the market. However, the company also faces challenges and uncertainties regarding the clinical trial outcomes and eventual approval.
Read more →ACXPAcurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
Acurx Pharmaceuticals, Inc. reported its financial and operational highlights for Q4 and the full year of 2023. The company announced successful results from its Phase 2b clinical trial of ibezapolstat, an antibiotic for C. difficile infection, achieving a 96% clinical cure rate. Despite positive clinical outcomes and regulatory support, Acurx faced increased net losses in 2023. The company now prepares for its Phase 3 clinical trial, anticipating a meeting with the FDA to discuss the trial's next steps.
Read more →ACXPAcurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update
Acurx Pharmaceuticals, Inc. has announced a conference call scheduled for March 18, 2024, to discuss their fourth quarter and full year 2023 financial results. The company is focused on developing Ibezapolstat, an antibiotic in Phase 3 trials targeting C. difficile infections. This compound has received fast-tracking from the FDA and is designed to preserve the gut microbiome while combating bacterial infections. However, the company faces uncertainties regarding clinical trial outcomes and regulatory approval.
Read more →ACXPAcurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development
Acurx Pharmaceuticals announced key regulatory milestones for its antibiotic ibezapolstat, designated for treating C. difficile infections. The FDA has confirmed an End of Phase 2 meeting scheduled for late April 2024 to finalize the Phase 3 development plan following successful Phase 2 trials. Furthermore, the European Medicines Agency has granted SME designation, benefiting Acurx with financial incentives for EU marketing authorization. Encouragingly, ibezapolstat demonstrated a clinical cure rate of 96% in the completed Phase 2 trials, positioning the company favorably as it seeks to advance its product to Phase 3 studies.
Read more →ACXPAcurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
Acurx Pharmaceuticals has announced promising results from its Phase 2b clinical trial of ibezapolstat, an antibiotic for treating CDI. The trial reported that all patients treated with ibezapolstat maintained clinical cure without recurrence over a three-month observation period. The company plans to engage with regulatory agencies and advance to international Phase 3 trials, building on its strong clinical efficacy data. Ibezapolstat has previously been recognized with FDA's QIDP and Fast-Track Designation, indicating its potential significance in the market for CDI treatments.
Read more →ACXPAcurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024
Acurx Pharmaceuticals, a late-stage biopharmaceutical company, announced that its CEO David P. Luci will present at The Microcap Conference from January 30 to February 1, 2024, in Atlantic City, New Jersey. The company is known for developing small molecule antibiotics aimed at difficult-to-treat bacterial infections. Acurx's innovative approach involves targeting Gram-positive bacteria, a vital area in antibiotic development. The event may enhance investor interest and clarify the company's path forward.
Read more →ACXPAcurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients
Acurx Pharmaceuticals announced positive results from its Phase 2b clinical trial of ibezapolstat for the treatment of C. difficile infection (CDI). The study showed high efficacy, with 94% of patients achieving eradication of C. difficile by Day 3, surpassing vancomycin's 71% rate. Ibezapolstat also preserved critical gut bacteria, enhancing the potential for reducing CDI recurrence. The company plans to meet with regulatory agencies to discuss advancing to Phase 3 trials, supported by favorable Phase 2 data and the anticipation of competitive pricing.
Read more →ACXPAcurx to present at the 42nd Annual J.P. Morgan Healthcare Conference
Acurx Pharmaceuticals, Inc. has announced that its CEO, David P. Luci, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. The presentation will highlight the company's focus on developing novel antibiotics for challenging infections. An audio webcast of the event will be available live and subsequently on Acurx's website.
Read more →ACXP▼ -12.5%on this news
Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure
Acurx Pharmaceuticals announced the successful results of its Phase 2b trial for ibezapolstat, a novel antibiotic for treating C. difficile infection. All 15 patients who achieved Clinical Cure (CC) remained free of CDI recurrence one month after treatment, resulting in a 100% sustained clinical cure (SCC) rate. In contrast, patients receiving the standard care of vancomycin experienced an 86% SCC. With additional analyses expected in Q1 2024, Acurx is preparing to meet globally with regulatory agencies to advance to international Phase 3 trials.
Read more →ACXPAcurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
Acurx Pharmaceuticals, Inc. announced its third quarter financial results and provided an update on its antibiotic candidate ibezapolstat for treating C. difficile infections. The company reported a high clinical cure rate of 96% from its Phase 2 trials, with no reported safety concerns, which supports its transition to Phase 3 trials. Financially, Acurx ended the quarter with $7.1 million in cash and recorded a net loss of $3.1 million, though this marked an improvement compared to the previous year. The ongoing advancements and favorable preliminary data increase optimism around ibezapolstat's potential in the market.
Read more →ACXP▼ -25%on this news· ran to -35% by day 1
Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection
Acurx Pharmaceuticals announced successful results from its Phase 2 clinical trials for ibezapolstat, achieving a 96% clinical cure rate in patients with C. difficile infection. The treatment was well tolerated and met the primary efficacy endpoint after 10 days of oral administration. The company plans to proceed with preparations for an End-of-Phase 2 FDA Meeting and will advance into Phase 3 clinical trials. Following consultation with medical advisors, Acurx terminated the Phase 2b segment early due to strong results and will provide further analyses on secondary endpoints in the future.
Read more →ACXPAcurx Pharmaceuticals to Discuss Third Quarter 2023 Financial Results and Provide Business Update
Acurx Pharmaceuticals, Inc. will host a conference call on November 14, 2023, to discuss their third quarter financial results and business updates. The company is advancing its Phase 2 clinical trial of ibezapolstat, a new antibiotic targeting C. difficile infections. Initial data from previous trial segments show effective results, including a complete cure rate in early patient cohorts. Acurx continues to explore the drug's efficacy and mechanisms, focusing on its potential benefits in reducing recurrence rates.
Read more →ACXP▼ -12.8%on this news· ran to -29% by day 3
Acurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific Conferences
Acurx Pharmaceuticals, Inc. has announced significant scientific presentations regarding its antibiotic, ibezapolstat, at two key conferences, ClostPath 2023 and IDWeek 2023. The company shared findings on ibezapolstat’s effects on C. difficile, demonstrating its potential to reduce toxin production and its effectiveness compared to established treatments. Following the discontinuation of the Phase 2b clinical trial due to positive results, Acurx aims to advance Ibezapolstat into Phase 3 trials, bolstered by promising data and regulatory designations from the FDA.
Read more →ACXP▼ -6%on this news
Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection
Acurx Pharmaceuticals has successfully completed and discontinued the Phase 2b trial of ibezapolstat for treating C. difficile infection due to positive results. Both ibezapolstat and the control antibiotic vancomycin showed high clinical cure rates without safety issues. The company is now set to analyze the trial data and will expedite the progression of ibezapolstat to Phase 3 clinical trials, supported by favorable preliminary findings. This antibiotic candidate is FDA QIDP/Fast Track-designated, highlighting its significance in addressing urgent medical needs.
Read more →ACXPAcurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress
Acurx Pharmaceuticals announced progress in its pol IIIC research and development pipeline during a presentation at the World Antimicrobial Resistance Scientific Congress. The company is currently enrolling patients in a Phase 2b trial for the antibiotic Ibezapolstat, targeting C. difficile infections, and is approaching its enrollment goal of 36 patients for an interim analysis. Acurx also discussed its Gram Positive Selective Spectrum (GPSS) program, which focuses on treating systemic infections caused by gram-positive bacteria such as MRSA and VRE. The company has received positive designations from the FDA, facilitating advancement in its clinical trials.
Read more →ACXPAcurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023
Acurx Pharmaceuticals, a clinical-stage biopharmaceutical firm, announced that CEO David P. Luci will present at the H.C. Wainwright 25th Annual Global Investment Conference, set to take place from September 11-13, 2023. Investors can access the presentation online starting at 7 AM ET. The company focuses on developing new antibiotics targeting various antibiotic-resistant bacteria, including MRSA and VRE, showcasing its innovative approach within the biopharmaceutical sector.
Read more →ACXP▼ -8.4%on this news
7:01 am ET on Monday
Acurx Pharmaceuticals, Inc. announced its financial results for Q2 2023, including a stable cash position of $9.1 million and a net loss of $3.4 million. The company reported increased research and development expenses related to advancing their clinical trial for ibezapolstat, targeting C. difficile infections. Phase 2a results showed promising outcomes, including complete eradication of the bacteria by day three of treatment. Acurx is now progressing to the Phase 2b trial segment with broader patient enrollment at multiple clinical sites.
Read more →ACXP▼ -8.4%on this news
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update
Acurx Pharmaceuticals, Inc. reported its second quarter 2023 results, highlighting progress in its Phase 2b clinical trial for C. difficile infection. The company expects to complete patient enrollment for an interim review soon and has received approval to present its findings at upcoming prestigious conferences. However, Acurx reported an increased net loss and faced challenges with grant funding for its pre-clinical candidates, indicating financial pressures amidst ongoing clinical progress.
Read more →ACXPAcurx Pharmaceuticals to Discuss Second Quarter 2023 Financial Results and Provide Business Update
Acurx Pharmaceuticals announced it will discuss its Q2 2023 financial results and provide a business update on August 14, 2023. The focus will be on the progress of ibezapolstat, a new antibiotic being tested for Clostridioides difficile infection (CDI). The ongoing Phase 2 clinical trial, following a successful Phase 2a segment showing complete infection eradication, aims to evaluate the drug's efficacy and its microbiome impact. This advancement may lead to improved treatment options for CDI, a significant healthcare concern in the U.S.
Read more →ACXPAcurx Pharmaceuticals to Present at the Emerging Growth Conference on July 12, 2023
Acurx Pharmaceuticals, Inc. will present at the Emerging Growth Conference on July 12, 2023. CEO David P. Luci will provide insights on the company’s initiatives, particularly their development of new antibiotics targeting difficult bacterial infections. The presentation will be available via webcast and archived for 30 days. Acurx's pipeline includes candidates aimed at treating antibiotic-resistant diseases such as MRSA and VRE.
Read more →ACXPAcurx Pharmaceuticals to Participate in the Maxim Group LLC Virtual Healthcare Conference on Tuesday, June 20, 2023 to Thursday, June 22, 2023 at 9 am ET
Acurx Pharmaceuticals will be represented by CEO David P. Luci at the Maxim Group Virtual Healthcare Conference from June 20 to June 22, 2023. The conference will focus on innovative healthcare solutions, with multiple biotech and medical device companies participating. Acurx is centered on developing new antibiotics targeted at difficult bacterial infections, which are crucial in the current healthcare landscape. This event marks a significant opportunity for the company to highlight its pipeline and engage with potential investors.
Read more →ACXP▼ -7.4%on this news
Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering
Acurx Pharmaceuticals, Inc. has announced the pricing of a $4.0 million registered direct offering of its common stock. The company will sell 1,333,333 shares at a price of $3.00 per share to a single institutional investor in a transaction expected to close on May 18, 2023. Additionally, the transaction includes a concurrent private placement of unregistered warrants, which reflects ongoing efforts to secure funding for Acurx's antibiotic development programs targeting difficult bacterial infections. The proceeds from this offering are projected to be used for its research and development initiatives.
Read more →ACXP▼ -8.5%on this newsshared move
Acurx Pharmaceuticals, Inc. Reports First Quarter 2023 Results and Provides Business Update
Acurx Pharmaceuticals reported its Q1 2023 financial results, indicating ongoing activities in its Phase 2b clinical trial for CDI. The trial involves 28 clinical sites and compares the efficacy of its antibiotic candidate ibezapolstat against the standard treatment, vancomycin. The company received FDA approval for a protocol amendment that will enable interim data review. Despite reporting a net loss and a decrease in cash reserves, Acurx continues to pursue funding opportunities and collaborations to support its research initiatives.
Read more →ACXPAcurx Pharmaceuticals to Discuss First Quarter 2023 Financial Results and Provide Business Update
Acurx Pharmaceuticals, Inc. has announced it will discuss its first quarter 2023 financial results on May 12, 2023. The company will also provide an update on its Phase 2 clinical trial for ibezapolstat, aimed at treating Clostridioides difficile infection (CDI). With the successful completion of the Phase 2a trial, where all patients demonstrated complete cure, Acurx now progresses to the Phase 2b trial to evaluate ibezapolstat against standard treatment, vancomycin.
Read more →ACXP▼ -5.1%on this news
Acurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference
Acurx Pharmaceuticals has showcased new findings related to ibezapolstat at the ECCMID 2023 conference, particularly highlighting its potential in treating C. difficile infections. The scientific presentation illustrated ibezapolstat's unique bactericidal action and effectiveness against resistant C. difficile strains. Furthermore, the company reported on its preclinical program aimed at developing new antibiotics for systemic gram-positive bacterial infections. Ibezapolstat is currently in a Phase 2b clinical trial, with promising past results reinforcing its potential as a treatment option.
Read more →ACXPFDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific Conference
Acurx Pharmaceuticals announced that the FDA has accepted its Interim Analysis Plan for the Phase 2b clinical trial of ibezapolstat, aimed at treating C. difficile Infection (CDI). The trial will have an Independent Data Monitoring Committee review data once 36 patients are enrolled. Additionally, Acurx will present findings related to ibezapolstat's pharmacologic properties and updates on their antibiotic development at the ECCMID 2023 scientific conference.
Read more →ACXPAcurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update Staten Island, NY
Acurx Pharmaceuticals, Inc. reported its financial results for Q4 and the full year 2022, revealing a net loss increase to $3.3 million for Q4. The company's cash reserves decreased to $9.1 million compared to the previous year. Increased research and development expenses were attributed to ongoing Phase 2b trials for their new antibiotic, ibezapolstat, aimed at treating Clostridioides difficile infections. Despite financial losses, the company is progressing in its clinical development pipeline.
Read more →ACXPAcurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update
Acurx Pharmaceuticals is scheduled to discuss its financial results for Q4 2022 and the full year on March 16, 2023. The company is currently advancing its Phase 2 clinical trial for ibezapolstat, aimed at treating Clostridioides difficile infection (CDI). Results from the completed Phase 2a segment demonstrated complete eradication of infection, and the ongoing Phase 2b trial will compare the efficacy of ibezapolstat to vancomycin. The firm focuses on developing new antibiotics for difficult-to-treat infections, particularly targeting Gram-positive bacteria.
Read more →ACXP▼ -5.9%on this news
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023
Acurx Pharmaceuticals has announced its participation in the Emerging Growth Conference scheduled for January 25, 2023. The event will feature an interactive session led by CEO David P. Luci, allowing investors the opportunity to ask questions. Acurx is focused on a new class of antibiotics for difficult bacterial infections, which positions the company attractively in the healthcare market.
Read more →ACXP▲ +12.4%on this news
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results and Provides Business Update
STATEN ISLAND, N.Y., Nov. 14, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financia
Read more →ACXPAcurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022 Conference Call and Provide Business Update
STATEN ISLAND, N.Y., Nov. 1, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company
Read more →ACXPAcurx Announces Scientific Oral and Poster Presented at IDWeek 2022
Presents research on ibezapolstat's selective activity on healthy bacteria within the gut microbiome in the treatment of C. difficile Infection (CDI) Emerging ibezapolstat microbiome data demonstrate that favorable effects seen in the Ph1 healthy volunteer study are also observe
Read more →ACXPAcurx Announces Scientific Oral and Poster Presentations at IDWeek
New emerging, favorable microbiome data to be presented from previously completed Ph1 healthy volunteers and Ph2a patients with C. difficile Infection clinical trials Extends research on ibezapolstat's selective activity compared to healthy bacteria within the gut microbiome in
Read more →ACXPAcurx Pharmaceuticals, Inc. Reports Second Quarter 2022 Results and Provides Business Update
STATEN ISLAND, N.Y., Aug. 15, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financia
Read more →ACXPAcurx Pharmaceuticals, Inc. to Discuss 2022 Second Quarter Financial Results on August 16, 2022 Conference Call and Provide Business Update
STATEN ISLAND, N.Y., Aug. 4, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company
Read more →ACXPAcurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI at the 16th Biennial Congress of the Anaerobe Society of America
New data link beneficial microbiome changes in Ph2a CDI patients to earlier results from Ph1 healthy volunteers to predict potential anti-recurrence properties of ibezapolstat New in vitro data show ibezapolstat is effective against high bacterial concentration (inoculum) of C.
Read more →ACXPAcurx Pharmaceuticals, Inc. Announces $4.225 Million Registered Direct Offering
Acurx Pharmaceuticals, Inc. Announces $4.225 Million Registered Direct Offering NY., July 25, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical-stage biopharmaceutical company developing a new class of antibiotics for diffic
Read more →ACXPAcurx Pharmaceuticals, Inc. Reports First Quarter 2022 Results and Provides Business Update
STATEN ISLAND, N.Y., May 11, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial
Read more →ACXPAcurx Pharmaceuticals, Inc. to Discuss 2022 First Quarter Financial Results on May 11, 2022 Conference Call and Provide Business Update
STATEN ISLAND, N.Y., April 29, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Compan
Read more →ACXP7:01 am ET on Thursday
For Immediate Release - 7:01 am ET on Thursday, March 17, 2022 Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update Staten Island, NY, March 17, 2022 - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"
Read more →ACXPAcurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update
STATEN ISLAND, N.Y., March 17, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financi
Read more →ACXPAcurx Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28-30, 2022 from 9:00 a.m. - 5:00 p.m. EDT
STATEN ISLAND, N.Y., March 16, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that Company's
Read more →ACXP▲ +8.7%on this news
Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update
STATEN ISLAND, N.Y., March 7, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company
Read more →ACXPAcurx Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectious Diseases
STATEN ISLAND, N.Y., Feb. 7, 2022 /PRNewswire/ -- Publication of study presents: Clinical results of 10 of 10 patients (100%) enrolled met the study's primary and secondary efficacy endpoints of Clinical Cure at end of treatment and Sustained Clinical Cure of no recurrence of C
Read more →ACXP▲ +5.3%on this news
Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI)
STATEN ISLAND, N.Y., Dec. 6, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the first pa
Read more →ACXPAcurx Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides Business Update Staten Island, NY
Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides Business Update Island, NY, November 12, 2021 - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for diff
Read more →ACXP▲ +5.6%on this news
Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference
STATEN ISLAND, N.Y., Nov. 8, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that new microbio
Read more →ACXPAcurx Pharmaceuticals to Discuss 2021 Third Quarter Financial Results on November 15, 2021 Conference Call and Provide Business Update
STATEN ISLAND, N.Y., Oct. 27, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company
Read more →ACXP▼ -10.6%on this news
Acurx Presents Positive Ibezapolstat Microbiome Data from Its Phase 2a Trial at IDWeek
STATEN ISLAND, N.Y., Oct. 4, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a scientific
Read more →ACXP▲ +9.2%on this newsshared move
Acurx Pharmaceuticals to Participate in the A.G.P. Biotech and Specialty Pharma Conference October 13, 2021
STATEN ISLAND, N.Y., Sept. 29, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that management
Read more →ACXPAcurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI in a Scientific Poster Presentation at IDWeek 2021 Conference
STATEN ISLAND, N.Y., Sept. 27, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a scientif
Read more →ACXPAcurx Pharmaceuticals to Join the Russell Microcap Index®
STATEN ISLAND, N.Y., Sept. 2, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company
Read more →ACXP▲ +5.1%on this news· ran to +17% by day 3shared move
Acurx Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
STATEN ISLAND, N.Y., Aug. 31, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that David P. Lu
Read more →ACXP▼ -11.9%on this news
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2021 Results and Provides Business Update Successful June 2021 IPO Raising $17.25 million in Gross Proceeds Including Exercise of Overallotment Opt
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2021 Results and Provides Business Update Successful June 2021 IPO Raising $17.25 million in Gross Proceeds Including Exercise of Overallotment Option Staten Island, NY, August 16, 2021 - Acurx Pharmaceuticals, Inc. (NASDAQ:
Read more →ACXP▼ -11.9%on this news
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2021 Results and Provides Business Update
STATEN ISLAND, N.Y., Aug. 16, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financia
Read more →ACXPAcurx Pharmaceuticals to Present at the Emerging Growth Conference on August 18, 2021
STATEN ISLAND, N.Y., Aug. 12, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that David P. Lu
Read more →ACXPHealth Holland Awards Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals
STATEN ISLAND, N.Y., Aug. 2, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company") a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that Health Holland
Read more →ACXPAcurx Pharmaceuticals to Discuss 2021 Second Quarter Financial Results on August 17, 2021 Conference Call and Provide Business Update
STATEN ISLAND, N.Y., July 28, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company
Read more →ACXPAcurx Announces Filing of Provisional Patent Application for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving the Health of the Gut Microbiome
STATEN ISLAND, N.Y., July 7, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company") a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that it has filed a
Read more →ACXPACURX PHARMACEUTICALS, INC. announces pricing of $15 Million underwritten INITIAL public offering of common stock
PHARMACEUTICALS, INC. announces pricing of $15 Million INITIAL public offering of common stock STATEN ISLAND, N.Y., June 25, 2021 - Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) (the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for
Read more →Competitive Position
How ACXP ranks across every disease it competes inCompetitive Position is a premium feature
See how ACXP ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial